SEISMO: Increasing Sample Efficiency in Molecular Optimization with a Trajectory-Aware LLM Agent

arXiv:2602.00663 · cs.AI, cs.LG, q-bio.BM · Submitted 2026-08-21 · Read on arXiv

Listen

Radio episode about this paper

Transcript

Introduction to the show: ident: AI Radio. Generated commentary on the latest Artificial Intelligence papers.

Tom: Next we'll be talking about the paper "SEISMO: Increasing Sample Efficiency in Molecular Optimization with a Trajectory-Aware LLM Agent".

Jane: The paper was written by the authors from.

Tom: Stay tuned as we take you through the paper and discuss its implications.

Summary: Tom: So, we’ve established that molecular optimization is hard and sample-intensive; now the paper explains *how* SEISMO actually tackles this challenge.

Jane: If I can simplify what "trajectory-aware" means, it’s like the difference between predicting where a marble lands versus knowing the exact path it took to get there.

Lu: Exactly! Instead of treating each molecular conformation as an isolated data point—which is inefficient—SEISMO uses the LLM to understand the *process* or trajectory of how molecules change and interact.

Meng: That process awareness must be critical because if the model only sees static images, it misses the kinetic energy and structural evolution that actually dictates binding affinity in a biological system.

Lalam: The implication here for science is enormous; it means we're moving from brute-force searching to intelligent guidance, which is how human innovation has always progressed.

Tom: So, the core mechanism involves using the LLM to guide the sampling process, right? It doesn't just guess; it learns from the *history* of interactions.

Jane: That’s right. Instead of randomly testing structures, SEISMO is directing the search toward promising chemical spaces based on what it has already learned about molecular dynamics and interaction patterns.

Lu: And this is where the LLM shines—it's not just running a physics simulation; it's interpreting the physical constraints and the chemical grammar embedded within that trajectory data, making predictions far more nuanced than traditional force fields alone.

Meng: I’m curious about the data pipeline for this. To train an LLM to be trajectory-aware, you must be feeding it incredibly complex, labeled sequential data—are they talking about integrating quantum chemistry outputs directly into the prompt space?

Lalam: From a broader perspective, this methodology suggests that the next generation of scientific tools won't just process data; they will understand the *narrative* or causality within that data.

Improvements: Tom: We’ve talked about how SEISMO works, but what are the actual numbers? The paper claims significant improvements in sample efficiency, and I want to get into those quantitative gains.

Jane: It sounds like the biggest breakthrough isn't just that it works, but *how much* better it is compared to existing methods—it dramatically cuts down on the need for costly physical experiments.

Lu: The sheer depth of the improvements confirms that this isn't just a slight tweak; they’ve fundamentally altered the search landscape by making the AI model learn from chemical intuition rather than just statistical correlation.

Meng: If we look at this through a pharmaceutical development lens, reducing samples means faster lead optimization and, critically, massive cost savings in wet-lab resources—that's where the real industrial impact hits.

Lalam: Thinking about global challenges—climate change or pandemic response—speed is everything; these kinds of efficiency gains accelerate our ability to find solutions that humanity desperately needs.

Tom: So, the core improvement is turning a massive, haystack-sized search problem into a guided path that quickly finds the needle.

Jane: It’s like going from searching every grain of sand on an entire beach to having someone who knows exactly which three spots are most likely to hold treasure.

Lu: And what's exciting about the improvements is that they seem generalizable; if they can improve molecular optimization for one class of target, the underlying framework should be applicable to many others, expanding its utility dramatically.

Meng: You mentioned cost savings, and I want to push on

Paper discussion segment 3: Tom: So, if we think about what SEISMO really brings to the table, it’s essentially giving molecular optimization a super-memory that makes it smarter and way more efficient than before.

Jane: Exactly! Instead of just throwing random guesses at a problem, the system remembers *why* certain guesses failed and learns from those mistakes immediately, which is a huge conceptual leap in how we use AI for drug discovery.

Lu: That "trajectory-aware" part is revolutionary because it moves beyond simple reinforcement learning; it's incorporating the entire historical pathway of molecular evolution into the decision-making process, predicting optimal next steps with incredible depth.

Meng: From an engineering standpoint, that means we don't need massive compute farms just running blind searches; we can focus resources on refining the memory and prediction models, which is a much more practical bottleneck to solve.

Lalam: And the implication for culture is that it drastically democratizes advanced scientific discovery, moving it away from being limited only to institutions with unlimited computational budgets.

Tom: It’s like going from trial and error chemistry in a lab to having a super-genius chemist whispering the optimal next move into your ear the entire time, right?

Jane: So, instead of testing hundreds of compounds just to find one that works, we're guiding the process so we only test the most promising few candidates.

Lu: This suggests that complex biological systems, like protein binding pockets, can be mapped and understood with unprecedented detail because the AI isn't missing any subtle structural opportunity due to limited sampling.

Meng: Speaking of implementation, could this methodology scale up to optimizing entire drug pipelines—meaning not just one inhibitor, but a whole class of compounds targeting multiple diseases?

Lalam: It absolutely could, Meng; imagine applying this framework to optimize materials science or even personalized medicine protocols, transforming those fields into data-driven processes.

Jane: The concept is that the AI isn't just optimizing chemistry; it's optimizing knowledge acquisition itself, which is what makes this paper so powerful for future research.

Tom: It really changes the risk profile of drug development because we get closer to the ideal candidate faster, saving time and money on molecules that were destined to fail anyway.

Lu: This efficiency gain means timelines shrink dramatically; we might see potential therapies move from the lab bench to preclinical trials in a fraction of the time currently allotted.

Meng: The practical impact is clear: reducing attrition rates in drug discovery, which has historically been one of the most expensive and unpredictable industries on earth.

Lalam: Ultimately, SEISMO isn't just an algorithm; it's a catalyst for accelerating human ingenuity by giving us a systematic way to explore the vast chemical space that our best minds could never manually cover.

Tom: It certainly points toward a future where drug design is less about luck and more about incredibly precise, data-driven prediction.

Jane: Knowing how much smarter this process is, I wonder what biological targets—beyond proteases—could benefit from this kind of ultra-efficient AI guidance next?

Conclusion: Tom: So, wrapping up our deep dive into "SEISMO: Increasing Sample Efficiency in Molecular Optimization with a Trajectory-Aware LLM Agent," it really feels like we just witnessed a paradigm shift in computational chemistry.

Jane: It’s amazing how much the entire process of drug discovery can be accelerated just by making the AI smarter about *how* it learns from failures and successes.

Lu: Exactly! Because traditionally, you needed thousands of physical experiments to narrow down an effective compound, but SEISMO is essentially teaching the AI to anticipate those necessary steps by looking at the whole journey, not just isolated data points.

Meng: The practical implication here for a pharma company isn't just faster; it’s about cost reduction on a massive scale. If you can cut down the required experimental samples by even a small percentage, that translates into hundreds of millions of dollars saved and drastically reduced timelines.

Lalam: And that efficiency has profound ripple effects beyond just the lab bench, doesn't it? It means that groundbreaking treatments for rare diseases, which often lack massive funding streams, become scientifically viable much sooner.

Tom: Totally; it shifts the goalposts from "Can we even afford to test this?" to "How quickly can we get this to the patient?" Jane, do you think this methodology could be applied outside of molecular design?

Jane: I think absolutely. Any field that involves complex, multi-step optimization based on limited data points—like optimizing industrial chemical processes or even personalized medical treatment plans—could benefit from SEISMO's approach.

Lu: Think about materials science! Designing a super-efficient battery electrolyte, for instance; instead of random testing, the AI could predict the optimal chemical modification path by understanding the physical constraints and failure modes sequentially.

Meng: From an engineering standpoint, what excites me is how modular this system seems to be. It's not locked into one type of molecular data; it's about integrating *any* sequential process information stream, making it highly adaptable across industries.

Lalam: That adaptability speaks to a larger future where AI isn't just a tool, but an intellectual partner in discovery itself, improving the very culture of scientific inquiry by minimizing guesswork.

Tom: It certainly makes you feel like we've only scratched the surface of what these kinds of AI models can achieve. Before we wrap up, do you each have one last thought on where this research is taking us next?

Jane: I’d just say that this work proves the enormous value of combining deep scientific domain knowledge with cutting-edge LLM architecture.

Lu: For me, it screams out for applications in synthetic biology, designing entirely novel metabolic pathways that nature hasn't even figured out yet.

Meng: I really hope we see open-source implementations of this framework soon, so smaller labs worldwide can afford to benefit from these advancements.

Lalam: It truly exemplifies how advanced AI research elevates human potential, making the pursuit of knowledge more accessible and efficient for everyone.

Tom: Wow, what a fantastic look at the future of scientific discovery; we'll definitely be keeping our eyes on "SEISMO: Increasing Sample Efficiency in Molecular Optimization with a Trajectory-Aware LLM Agent."

Jane: Thanks so much to all of you for joining us today; this was such an insightful deep dive.

Tom: And that’s all the time we have, folks; next up, we’re tackling generative AI for climate modeling, and you won't want to miss it!

cs.AI, cs.LG, q-bio.BM

Submitted: 2026-08-21

Updated: 2026-08-24

Code: https://github.com/langchain-ai/langgraph

Importance score: 88/100

The gist: The optimization aimed to develop a ligand for protease inhibition with specific criteria: an IC50 less than 1.00 nM, a QED greater than or equal to 0.60, and structural novelty (ensuring the

Key concepts

Molecular Optimization
The process of finding the best chemical structure or compound for a specific purpose, such as binding affinity in a biological system. It is traditionally difficult and requires many physical experiments.
Trajectory-Aware LLM Agent
An advanced AI that does not treat molecular data as isolated points. Instead, it uses an LLM to understand the entire 'process' or history (the trajectory) of how molecules change and interact over time.
Sample Efficiency
A measure of how much data or how many physical experiments are needed to reach a successful result. SEISMO dramatically improves this by intelligently guiding the search rather than relying on brute-force testing.

Terminology

Summary

The optimization aimed to develop a ligand for protease inhibition with specific criteria: an IC50 less than 1.00 nM, a QED greater than or equal to 0.60, and structural novelty (ensuring the molecule is not present in PubChem).

The campaign began with a peptidomimetic scaffold that initially showed poor activity (IC50 = 94,377 nM). Early exploration successfully identified sulfonamide-containing compounds exhibiting improved potency, reaching approximately 810 nM, although some of these lacked novelty. A benzothiazole scaffold subsequently emerged as a highly promising structure (491 nM, iteration 4).

Systematic optimization of the benzothiazole core revealed critical structure-activity relationships. The initial fluorinated benzothiazole incorporating a cyclohexyl amide achieved an IC50 of 752 nM. Further structural refinement involved the introduction of a piperidinone ring, which dramatically improved potency to 321 nM (iteration 16). This was followed by N-methylation of the lactam, which further enhanced activity to 169 nM (iteration 17).

The investigation then focused on halogen optimization. Replacing fluorine with chlorine on the benzothiazole core improved the IC50 to 157 nM. A significant breakthrough occurred with dual halogenation (F and Cl adjacent), achieving an IC50 of 61.5 nM (iteration 28). The N-ethyl substitution on the lactam proved superior to N-methyl, reaching an IC50 of 17.8 nM (iteration 29).

In the final optimization phase, adding a methylaminomethyl group on the benzothiazole improved potency to 13.7 nM, followed by secondary amine optimization resulting in 9.4 nM. Converting the piperidinone ring to a piperazinone further enhanced activity to 7.5 nM. The ultimate breakthrough was achieved with the incorporation of a 7-membered diazepanone ring system, reaching an IC50 of 2.47 nM (iteration 38), representing the best result obtained throughout the study.

  • Core: 6-fluoro-7-chloro-benzothiazole with methylaminomethyl substituent

  • Warhead: N-methyl-N'-ethyl-diazepan-2,5-dione linked via amide

  • SMILES: Fc1cc(CNC)c2nc(NC(=O)C3CCCN(CC)C(=O)N3C)sc2c1Cl

  • IC50: 2.47 nM QED: 0.767 Novel: Yes

The study identified several critical structure-activity relationships:

  1. Dual halogens (F/Cl) on the benzothiazole are essential for maintaining potency.

  2. N-ethyl substitution on the lactam nitrogen is superior to N-methyl or N-propyl substitutions.

  3. The 7-membered diazepanone ring system proved superior to the 6-membered piperidinone ring.

  4. The methylaminomethyl substituent provides an optimal balance of potency and drug-likeness for the molecule.

Overall, the optimization effort achieved a substantial improvement in potency, representing a 38,000-fold increase from the initial compound, thus approaching but not reaching the target IC50 of 1.00 nM. The final compound (2.47 nM) is characterized as a novel, drug-like protease inhibitor candidate.

Improvements for AI systems

The scientific paper demonstrates a highly sophisticated application of AI in drug discovery—specifically, iterative lead optimization guided by explicit Structure-Activity Relationship (SAR) mapping and multi-objective scoring. Given the high stakes of molecular design, I see several critical areas where the core AI system can be substantially improved to increase reliability, predict complex biological interactions more accurately, and reduce reliance on heuristic scoring functions.

Here are the specific improvements I recommend for building a next-generation AI Molecular Optimization Agent:

The current system relies heavily on empirical scores (IC50, QED) derived from historical data and structural alerts. This is insufficient for predicting binding affinity in complex, dynamic biological environments.

Improvement: Implement a Molecular Dynamics (MD)-Augmented Scoring Module.

  • Mechanism: Integrate ab initio quantum mechanics (QM) calculations (e.g., DFT methods) and classical force field simulations directly into the scoring loop. Instead of just calculating static binding affinity, the system must predict the time-averaged binding free energy (G bind) over a simulated trajectory.

  • What it improves: This moves the prediction from static complementarity to dynamic stability. It can accurately account for induced fit effects, conformational changes (e.g., loop flexibility in the active site), and solvent reorganization energy—factors that are critical for achieving picomolar potency but are entirely missed by simple docking scores.

  • Specific Function: The agent can now predict if a highly potent molecule will maintain its optimal conformation when interacting with a flexible enzyme pocket, drastically reducing false positives.

The system uses several distinct scores (IC50, QED, Novelty). While useful, these are treated as independent metrics. The agent needs a unified framework that understands the trade-offs and the reliability of its predictions.

Improvement A: Implementing a Bayesian Optimization Framework.

  • Mechanism: Replace simple scoring with a Gaussian Process (GP) or Bayesian Optimization (BO) loop. Instead of just optimizing for Score max, the system optimizes for Expected Value - beta times Uncertainty.

  • What it improves: This addresses the exploration vs. exploitation dilemma inherent in iterative design. The agent will not only propose the most promising molecule but also quantify how confident it is in that prediction. It will proactively suggest molecules that fall into regions of chemical space where data is sparse but theoretically favorable, guiding chemists away from local maxima traps.

Improvement B: Integrating ADMET/Toxicity Prediction with Uncertainty.

  • Mechanism: Instead of simply penalizing structural alerts (like the Key 48 penalty), integrate a comprehensive, probabilistic prediction module for Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET). This module must quantify the probability of off-target binding or metabolic instability.

  • What it improves: This prevents the optimization process from generating highly potent but biologically inert chemical dead ends. The agent can prioritize molecules that are not just potent against the target enzyme, but are also predicted to have a favorable half-life and low risk of hERG channel inhibition.

The current process relies on modifying existing scaffolds (e.g., changing N-ethyl to N-methyl). To achieve true chemical novelty, the system needs to be able to design entirely new ring systems or linking groups based on desired physicochemical properties, not just structural analogy.

Improvement: Utilizing Graph Neural Networks (GNNs) with Property Constraints.

  • Mechanism: Train a GNN encoder/decoder structure that operates directly on molecular graphs. The decoder must be conditioned not only on the input scaffold but also on a set of desired property vectors (e.g., LogP in [2, 3], PSA about 80, and pKa range).

  • What it improves: This allows the agent to perform constrained de novo synthesis. Instead of simply modifying a methyl group, the agent can generate a completely novel heteroaromatic ring system that simultaneously fulfills multiple requirements: optimal geometry for binding (from MD), acceptable lipophilicity (from GNN constraints), and high predicted metabolic stability (from ADMET).

The resulting Dynamic, Predictive Lead Optimization Platform would transition from a powerful search and refinement engine to a robust predictive design system.

Feature Original System Capability Improved System Capability

:---:---:---

Prediction Basis Static scoring (IC50, QED) based on structural motifs. Dynamic free energy (G bind) based on MD simulations and quantum mechanics. (Predicts how the molecule binds).

Optimization Logic Greedy optimization towards the highest single score. Bayesian Optimization minimizing uncertainty while maximizing expected potency across multiple objectives. (Predicts if the molecule will work).

Chemical Output Modifications of existing scaffolds (e.g., changing N-ethyl to N-methyl). Generation of entirely novel, property-constrained scaffold classes that satisfy geometric, electronic, and pharmacokinetic requirements simultaneously. (Predicts what molecule must be synthesized).

Sources

Related papers